Top Markets
Coin of the day
Antibe Therapeutics Inc. Antibe Therapeutics Inc.

Antibe Therapeutics Inc.

ATE
Clasificación en acciones #32097
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Precio por acción
$0.21483059
Última sincronización: 2024-05-07
Capitalización bursátil
$11.13M
Cambio (1 día)
0.34%
Cambio (1 año)
0.00%
País
CA
Comercio Antibe Therapeutics Inc. (ATE)

Categoría

Historial de desdoblamientos de acciones de Antibe Therapeutics Inc. (ATE)
La acción Antibe Therapeutics Inc. (símbolo: ATE) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Aug 18, 2026.
Una acción ATE comprada antes de Aug 18, 2026 equivaldría hoy a 0 acciones ATE.
Lista de desdoblamientos de acciones
Año Desdoblamiento Multiplicador Multiplicador acumulado
Not enough data for the provided dates.
Desdoblamientos de acciones de empresas similares o competidoras
Empresa Número de desdoblamientos de acciones Multiplicador acumulado País
9 x285
US
9 x162
US
7 x127
IE
2 x4
US
3 x12
US